Cargando…

Efficacy of Bacillus coagulans BC01 on loperamide hydrochloride-induced constipation model in Kunming mice

In this study, the laxative effect of Bacillus coagulans BC01 (BC01) in mice was investigated using a functional constipation mouse model. Six-week-old male specific pathogen-free (SPF) Kunming mice were randomly divided into five groups: normal control group (saline), model group (loperamide hydroc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xu, Chen, Yafang, Ma, Xin, Yu, Yang, Yu, Xueping, Chen, Xiaoyong, Suo, Huayi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533339/
https://www.ncbi.nlm.nih.gov/pubmed/36211526
http://dx.doi.org/10.3389/fnut.2022.964257
_version_ 1784802322389401600
author Zhou, Xu
Chen, Yafang
Ma, Xin
Yu, Yang
Yu, Xueping
Chen, Xiaoyong
Suo, Huayi
author_facet Zhou, Xu
Chen, Yafang
Ma, Xin
Yu, Yang
Yu, Xueping
Chen, Xiaoyong
Suo, Huayi
author_sort Zhou, Xu
collection PubMed
description In this study, the laxative effect of Bacillus coagulans BC01 (BC01) in mice was investigated using a functional constipation mouse model. Six-week-old male specific pathogen-free (SPF) Kunming mice were randomly divided into five groups: normal control group (saline), model group (loperamide hydrochloride), drug control group (bisacodyl), BC01 low-dose group (4.0 × 10(8) CFU/mL) and BC01 high-dose group (4.0 × 10(9) CFU/mL). Except for the normal group, the functional constipation model was established by administering 0.25 mL of a loperamide hydrochloride suspension (1 mg/mL) twice daily for four consecutive days by oral gavage. After modeling, the BC01 groups were administered 0.25 mL of BC01. The bisacodyl served as a control and was administered orally at a dose of 100 mg/kg, while the other groups were administered 0.25 mL of sterile saline. After 7 days of continuous administration, the experimental mice were again induced by loperamide hydrochloride. During this period, the mechanism of BC01 to improve constipation symptoms in mice was analyzed by measuring the changes in body weight, fecal water content, small intestine propulsion rate, histology of small intestinal tissue sections, fecal microbial diversity, serum indices, as well as mRNA and protein expression levels in the small intestinal tissue. BC01 was found to significantly promote the intestinal propulsion rate and increase the fecal water content in the mice. BC01 could also alleviates constipation by regulating gastrointestinal motility (substance P, motilin, endothelin-1, somatostatin, and vasoactive intestinal peptide), gene expression (c-Kit, SCF, COX-2, NF-κB, iNOS, and eNOS), intestinal inflammation (eNOS, iNOS, NF-κB), and the intestinal microbiota composition in the constipated mice. In addition, the high-dose BC01 treatment had the best preventive effect on constipation. BC01 is a probiotic strain to effectively relieve the adverse effects of constipation.
format Online
Article
Text
id pubmed-9533339
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95333392022-10-06 Efficacy of Bacillus coagulans BC01 on loperamide hydrochloride-induced constipation model in Kunming mice Zhou, Xu Chen, Yafang Ma, Xin Yu, Yang Yu, Xueping Chen, Xiaoyong Suo, Huayi Front Nutr Nutrition In this study, the laxative effect of Bacillus coagulans BC01 (BC01) in mice was investigated using a functional constipation mouse model. Six-week-old male specific pathogen-free (SPF) Kunming mice were randomly divided into five groups: normal control group (saline), model group (loperamide hydrochloride), drug control group (bisacodyl), BC01 low-dose group (4.0 × 10(8) CFU/mL) and BC01 high-dose group (4.0 × 10(9) CFU/mL). Except for the normal group, the functional constipation model was established by administering 0.25 mL of a loperamide hydrochloride suspension (1 mg/mL) twice daily for four consecutive days by oral gavage. After modeling, the BC01 groups were administered 0.25 mL of BC01. The bisacodyl served as a control and was administered orally at a dose of 100 mg/kg, while the other groups were administered 0.25 mL of sterile saline. After 7 days of continuous administration, the experimental mice were again induced by loperamide hydrochloride. During this period, the mechanism of BC01 to improve constipation symptoms in mice was analyzed by measuring the changes in body weight, fecal water content, small intestine propulsion rate, histology of small intestinal tissue sections, fecal microbial diversity, serum indices, as well as mRNA and protein expression levels in the small intestinal tissue. BC01 was found to significantly promote the intestinal propulsion rate and increase the fecal water content in the mice. BC01 could also alleviates constipation by regulating gastrointestinal motility (substance P, motilin, endothelin-1, somatostatin, and vasoactive intestinal peptide), gene expression (c-Kit, SCF, COX-2, NF-κB, iNOS, and eNOS), intestinal inflammation (eNOS, iNOS, NF-κB), and the intestinal microbiota composition in the constipated mice. In addition, the high-dose BC01 treatment had the best preventive effect on constipation. BC01 is a probiotic strain to effectively relieve the adverse effects of constipation. Frontiers Media S.A. 2022-09-21 /pmc/articles/PMC9533339/ /pubmed/36211526 http://dx.doi.org/10.3389/fnut.2022.964257 Text en Copyright © 2022 Zhou, Chen, Ma, Yu, Yu, Chen and Suo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nutrition
Zhou, Xu
Chen, Yafang
Ma, Xin
Yu, Yang
Yu, Xueping
Chen, Xiaoyong
Suo, Huayi
Efficacy of Bacillus coagulans BC01 on loperamide hydrochloride-induced constipation model in Kunming mice
title Efficacy of Bacillus coagulans BC01 on loperamide hydrochloride-induced constipation model in Kunming mice
title_full Efficacy of Bacillus coagulans BC01 on loperamide hydrochloride-induced constipation model in Kunming mice
title_fullStr Efficacy of Bacillus coagulans BC01 on loperamide hydrochloride-induced constipation model in Kunming mice
title_full_unstemmed Efficacy of Bacillus coagulans BC01 on loperamide hydrochloride-induced constipation model in Kunming mice
title_short Efficacy of Bacillus coagulans BC01 on loperamide hydrochloride-induced constipation model in Kunming mice
title_sort efficacy of bacillus coagulans bc01 on loperamide hydrochloride-induced constipation model in kunming mice
topic Nutrition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533339/
https://www.ncbi.nlm.nih.gov/pubmed/36211526
http://dx.doi.org/10.3389/fnut.2022.964257
work_keys_str_mv AT zhouxu efficacyofbacilluscoagulansbc01onloperamidehydrochlorideinducedconstipationmodelinkunmingmice
AT chenyafang efficacyofbacilluscoagulansbc01onloperamidehydrochlorideinducedconstipationmodelinkunmingmice
AT maxin efficacyofbacilluscoagulansbc01onloperamidehydrochlorideinducedconstipationmodelinkunmingmice
AT yuyang efficacyofbacilluscoagulansbc01onloperamidehydrochlorideinducedconstipationmodelinkunmingmice
AT yuxueping efficacyofbacilluscoagulansbc01onloperamidehydrochlorideinducedconstipationmodelinkunmingmice
AT chenxiaoyong efficacyofbacilluscoagulansbc01onloperamidehydrochlorideinducedconstipationmodelinkunmingmice
AT suohuayi efficacyofbacilluscoagulansbc01onloperamidehydrochlorideinducedconstipationmodelinkunmingmice